Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 50.0%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 1,200,000 shares, a growth of 50.0% from the March 31st total of 799,900 shares. Based on an average trading volume of 1,110,000 shares, the days-to-cover ratio is presently 1.1 days. Currently, 8.9% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Vincerx Pharma stock. Sage Rhino Capital LLC grew its holdings in Vincerx Pharma, Inc. (NASDAQ:VINC) by 1.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,703,413 shares of the company’s stock after purchasing an additional 16,476 shares during the quarter. Sage Rhino Capital LLC owned approximately 7.97% of Vincerx Pharma worth $1,720,000 at the end of the most recent reporting period. Institutional investors own 44.02% of the company’s stock.

Vincerx Pharma Trading Down 18.6 %

VINC opened at $0.73 on Friday. The stock has a market capitalization of $15.63 million, a PE ratio of -0.39 and a beta of 1.10. Vincerx Pharma has a 1-year low of $0.61 and a 1-year high of $9.37. The firm has a 50-day moving average price of $4.07 and a two-hundred day moving average price of $2.07.

Vincerx Pharma (NASDAQ:VINC) last issued its earnings results on Friday, March 29th. The company reported ($0.23) earnings per share (EPS) for the quarter. On average, research analysts predict that Vincerx Pharma will post -0.97 EPS for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Vincerx Pharma in a research report on Tuesday, April 9th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.